Offerings (SEC Form D)
Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.
Offerings at a glance — 1 offering, 2 filings (one row per SEC file number)
| File no. | Original Form D | Latest filing | Amendments | Offered (latest) | Sold (latest) | Industry (latest) |
|---|
| 021-406723 | Jul 19, 2021 EDGAR ↗ | Oct 29, 2021 D/A EDGAR ↗ | 1 latest Oct 29, 2021 | $15,299,999 | $15,299,999 | Pharmaceuticals |
Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.
Oct 29, 2021 D/A Pharmaceuticals — $15,299,999 sold of $15,299,999 · 43 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Oct 29, 2021 · amends 0001859637-21-000001 ↗SEC file no. 021-406723 · accession 0001104659-21-131756 · filing 2 of 2 in this offering |
|---|
| Raise progress | $15,299,999 sold of $15,299,999 offered (100%) · $0 remaining · first sale May 23, 2021 |
|---|
| Filing timing | Date of first sale: May 23, 2021 · Original Form D filed: Jul 19, 2021 (57 days after first sale) · This amendment (Form D/A) filed: Oct 29, 2021 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 1,980 days (5.4 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Oct 29, 2021. Most recent amendment for this offering in our index: this filing, Oct 29, 2021. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 43 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $20,000 |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed 2020 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Ron Bentsur, Chairman, CEO and President (Oct 29, 2021)
Ron Bentsur, Chairman, CEO and President (Oct 29, 2021) |
|---|
| Changes vs previous filing | - total sold: $11,280,000 (Jul 19, 2021) → $15,299,999 (Oct 29, 2021)
- total offering: $11,280,000 (Jul 19, 2021) → $15,299,999 (Oct 29, 2021)
- investors: 35 (Jul 19, 2021) → 43 (Oct 29, 2021)
- related persons added (Oct 29, 2021): Kenneth Hoberman, Uri Ben-Or, Shay Shemesh, James Oliviero, Matthew Kaplan, Enrique Poradosu
Compared with the D filed Jul 19, 2021 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Minimum investment: $20,000. Typical range for similar offerings: $10,000–$55,000.
Offering size: $15,299,999. Typical range: $1,694,259–$16,000,000.
Investors: 43. Typical range: 1–13."Similar" = Pharmaceuticals, Rule 506(b). Based on 800 Form D filings 2021–2026 in the same industry and exemption (Pharmaceuticals, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 186, offering size 758, investors 770. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jul 19, 2021 D Pharmaceuticals — $11,280,000 sold of $11,280,000 · 35 investors EDGAR ↗
| Filing | Form D filed Jul 19, 2021SEC file no. 021-406723 · accession 0001859637-21-000001 · filing 1 of 2 in this offering |
|---|
| Raise progress | $11,280,000 sold of $11,280,000 offered (100%) · $0 remaining · first sale May 23, 2021 |
|---|
| Filing timing | Date of first sale: May 23, 2021 · Form D filed: Jul 19, 2021 (57 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 1,980 days (5.4 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Oct 29, 2021 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 35 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $20,000 |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed 2020 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Pharmaceuticals |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Ron Bentsur, Director (May 23, 2021) |
|---|
| Market context | Minimum investment: $20,000. Typical range for similar offerings: $10,000–$55,000.
Offering size: $11,280,000. Typical range: $1,694,259–$16,000,000.
Investors: 35. Typical range: 1–13."Similar" = Pharmaceuticals, Rule 506(b). Based on 800 Form D filings 2021–2026 in the same industry and exemption (Pharmaceuticals, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 186, offering size 758, investors 770. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Amendment history — 1 amendment on this page, each compared with the filing before it in the same offering
| Amendment filed | File no. | Compared with | What changed (both values as filed) |
|---|
| Oct 29, 2021 EDGAR ↗ | 021-406723 | Jul 19, 2021 D | total sold: $11,280,000 (Jul 19, 2021) → $15,299,999 (Oct 29, 2021) · total offering: $11,280,000 (Jul 19, 2021) → $15,299,999 (Oct 29, 2021) · investors: 35 (Jul 19, 2021) → 43 (Oct 29, 2021) · and 1 more (open the filing above) |
Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.
All Form D filings for this CIK on SEC EDGAR ↗. Co-issuers on these filings: Nuvectis Pharma, Inc.. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Oct 29, 2021. Industry as reported, by offering: One offering, reported as Pharmaceuticals (Jul 19, 2021).
Key people 7
Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.
Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Connections
Other issuers listing the same people:
- Beyond Air, Inc. — Ron Bentsur · latest filing Oct 11, 2024
- Nuvectis Pharma, Inc. — Ron Bentsur · latest filing Aug 10, 2022
- Nuvectis Pharma, Inc. — Kenneth Hoberman · latest filing Aug 10, 2022
- Nuvectis Pharma, Inc. — Shay Shemesh · latest filing Aug 10, 2022
- Nuvectis Pharma, Inc. — James Oliviero · latest filing Aug 10, 2022
- Nuvectis Pharma, Inc. — Matthew Kaplan · latest filing Aug 10, 2022
- Nuvectis Pharma, Inc. — Enrique Poradosu · latest filing Aug 10, 2022
- Advanced Inhalation Therapies (AIT) Ltd. — Ron Bentsur · latest filing Feb 1, 2017
Shared address: this business address appears on filings for 6 other issuers. Stated as a count only (suite numbers ignored) — many addresses are shared office buildings or registered agents. As of Oct 23, 2026, 5:45 PM ET.
Address of record is shared by 7 issuers in SEC Form D filings (shared office, PartnerFacts count as of Oct 23, 2026, 5:45 PM ET) — not used to group this issuer.
Other offering types (Regulation A and Regulation Crowdfunding)
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Adviser registration (Form ADV)
Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched Centry Pharma, Inc..
Meta advertising
No Meta Pixel ids or Facebook / Instagram page links on file for Centry Pharma, Inc. as of Oct 24, 2026 — the sponsor website is read for them once it is on file (runs automatically). Meta Ad Library: not searched by PartnerFacts (no API access); a one-tap Ad Library search is under Look further.
Public profiles
Public profiles official links and public statements, each with its source and date
No website or social profile named in Centry Pharma, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #177,380 of 374,652 in line (14 issuers searched so far).
Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website comes from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim, Form ADV Item 1.I of its matched adviser, or a web search for the issuer name confirmed on the site's own homepage. We never collect personal or family accounts.
Entity standing: not checked (no official programmatic source for NJ yet).
Export this report as PDF (all source links + data timestamp) · Premium
Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".
Corrections log
No corrections have been requested for this page.
Filing-to-filing changes are in Amendment history above.